Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below Two Hundred Day Moving Average – Time to Sell?
by Teresa Graham · The Cerbat GemGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.45 and traded as low as $0.81. Galmed Pharmaceuticals shares last traded at $0.8512, with a volume of 105,517 shares.
Analyst Upgrades and Downgrades
GLMD has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen cut Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.
View Our Latest Report on GLMD
Galmed Pharmaceuticals Price Performance
The company has a market cap of $1.40 million, a P/E ratio of -2.66 and a beta of 0.31. The company’s 50-day moving average is $1.15 and its two-hundred day moving average is $1.45.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by institutional investors and hedge funds.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.
In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.